TENX Stock Overview
Develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Tenax Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.61 |
| 52 Week High | US$27.33 |
| 52 Week Low | US$2.77 |
| Beta | 2.19 |
| 1 Month Change | 14.02% |
| 3 Month Change | 64.52% |
| 1 Year Change | -77.31% |
| 3 Year Change | -99.66% |
| 5 Year Change | -99.75% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| TENX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.9% | -3.8% | -2.7% |
| 1Y | -77.3% | -2.6% | 23.4% |
Return vs Industry: TENX underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: TENX underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| TENX volatility | |
|---|---|
| TENX Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TENX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TENX's weekly volatility has decreased from 16% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 6 | Chris Giordano | www.tenaxthera.com |
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.
Tenax Therapeutics, Inc. Fundamentals Summary
| TENX fundamental statistics | |
|---|---|
| Market cap | US$19.12m |
| Earnings (TTM) | -US$14.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs TENX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TENX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$14.56m |
| Earnings | -US$14.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TENX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 21:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tenax Therapeutics, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seamus Fernandez | Guggenheim Securities, LLC |
| Vernon Bernardino | H.C. Wainwright & Co. |
| Jeffrey Cohen | Ladenburg Thalmann & Company |